secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010756
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax appoints Neil Gallagher as President, Head of R&D; Morrison transitions
------------------------------------------------------------------------------

- Neil Gallagher, M.D., Ph.D., appointed President, Head of R&D effective April 10, 2023; previously CMO at AbbVie.
- Briggs Morrison resigns as President, Head of R&D effective April 15, 2023; will consult for 3 months, remains on board.
- Gallagher receives $530k base salary, 45% target bonus, and inducement option for 250k shares vesting over 4 years.
- Company expects to advance revumenib and axatilimab through pivotal data and regulatory filings in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023010756/0000950170-23-010756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023010756/sndx-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer